Upcoming Medical Device Business Raising Funds In Bangalore

About Business

Device Types: Implants

Own RD Team: Yes

Inhouse Sterilisation: No

Patents Held Filed: Yes

Domestic vs Export Split: 100% domestic

Contract Mfg OEM Supply: No

Annual Production Value: 00

Bag-Free, On-Demand Peritoneal Dialysis Platform Executive Summary
Raising ₹2.5 Crore now (CCPS, ₹25 lakh minimum ticket)
Plus ₹2.5 Crore milestone-linked tranche (Q2 2027), tied to CDSCO Test License achievement
Total round: ₹5 Crore

Market Need; Challenges in India:
~220,000+ new End-Stage Renal Disease (ESRD) patients annually Up to 70% discontinue dialysis due to cost or access barriers.
Bulky, imported dialysate bags keep home-based therapy out of reach

KAREPD Product & Technology
Connected, automated home device
Generates pharmaceutical-grade dialysate on demand, directly from tap water
Cuts monthly consumable weight by ~96%
Cuts water use by ~85% (vs hemodialysis)
Built-in remote monitoring for clinician visibility and early detection
Two patent-pending core mechanisms: nano-precision dosing and non-contact sterile mixing

Business Model
Revenue streams: device rental → single-use consumables → annual maintenance contract → recurring revenue
Sold to dialysis chains and hospitals; fits within India's PMNDP reimbursement parameters

Traction
DPIIT and MSME recognised
Multiple non-dilutive government grants secured
"Most Impactful Health Innovation" across ASEAN and India (ERIA)
₹65 lakh in term sheets signed to date

The Founding Team:
The company was founded by three complementary operators who between them cover the commercial, technical, and strategic ground a medical device company has to hold at once.

The Chief Executive anchors execution and partnerships. She is responsible for turning a hard engineering programme into a company that ships — building the clinical, institutional, and commercial relationships a regulated device business depends on, and holding the organization to delivery timelines. In a sector where the distinction between a promising prototype and a marketable product is almost entirely a matter of execution discipline, this is the seat that determines outcomes.

The Chief Technology Officer leads engineering and innovation. The company's differentiation rests on miniaturization, mechatronics, and precision control — the capabilities that make a gravity-independent home dialysis device possible at all — and he owns that technical stack end to end. The core IP and the product roadmap sit under his remit.

The Chief Strategy Officer drives strategy and go-to-market. His focus is how the technology reaches patients and payers: market positioning, commercialization pathways, and the sequencing of domestic and international expansion. For a device targeting both a large underserved home market in India and export opportunity abroad, this function shapes the revenue story as much as the product does.

Together, the three founders are building from Bengaluru, supported by a clinical and regulatory bench and a network of institutional innovation partners.

Clientele type

NA

Premises

The premises are leased.

Use of Funds

The terms of the transaction will be discussed with potential investors.

Asking Price

INR 5.00 Cr

Minimum ticket size

INR 2.50 Cr

Reason

Invest in technology / R&D

Working capital / inventory

Product development / launch

Technology / platform development